Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended December 2022, Abbott (ABT - Free Report) reported revenue of $10.09 billion, down 12% over the same period last year. EPS came in at $1.03, compared to $1.32 in the year-ago quarter.

The reported revenue represents a surprise of +6.47% over the Zacks Consensus Estimate of $9.48 billion. With the consensus EPS estimate being $0.90, the EPS surprise was +14.44%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales-Diagnostics-US: $1.70 billion versus the four-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of -29%.
• Net sales-Nutritionals-International: $1.02 billion compared to the $1.04 billion average estimate based on four analysts. The reported number represents a change of -8.3% year over year.
• Net sales-Nutritionals-US: $795 million versus $787.80 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -14.3% change.
• Net sales-Diagnostics-International: $1.32 billion versus $1.51 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -36.8% change.
• Net sales-Nutritionals: $1.82 billion versus $1.85 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -11% change.
• Net sales-Established Pharmaceuticals: $1.22 billion compared to the $1.17 billion average estimate based on five analysts. The reported number represents a change of +1.1% year over year.
• Net sales-Medical-Abbott diabetes care: $1.27 billion versus $1.15 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.5% change.
• Net sales-Diagnostics: $2.24 billion versus $2.77 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -50% change.
• Net sales-Medical-Vascular- Total: $605 million versus the four-analyst average estimate of $613.96 million. The reported number represents a year-over-year change of -10.8%.
• Net sales-Structural Heart-Total: $441 million compared to the $426.62 million average estimate based on four analysts. The reported number represents a change of +5.3% year over year.
• Net sales-Heart Failure-Total: $230 million compared to the $228.57 million average estimate based on four analysts. The reported number represents a change of -3.8% year over year.
• Net sales-Electrophysiology-Total: $487 million compared to the $483.83 million average estimate based on four analysts. The reported number represents a change of -3.4% year over year.

View all Key Company Metrics for Abbott here>>>

Shares of Abbott have returned +3.7% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Free Report: Must-See Energy Stocks for 2023

Record profits at oil companies can mean big gains for you. With soaring demand and elevated prices, oil stocks could be top performers by far in 2023. Zacks has released a special report revealing the 4 oil stocks experts believe will deliver the biggest gains. (You’ll never guess Stock #2!) 

Download Oil Market on Fire today, absolutely free.